Barriers and Strategies for Oral Peptide and Protein Therapeutics Delivery: Update on Clinical Advances
Pharmaceutics · 21.03.2025 · 17 (4) · 397
DOI: 10.3390/pharmaceutics17040397 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 21.03.2025. Verfasst von Kshitis Chandra Baral und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Marine Bio-Food Science, Gangneung-Wonju National University, Gangneung 25457, Republic of Korea. Die Arbeit wurde bisher 144-mal zitiert (Crossref) und nennt 161 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Ministry of SMEs and Startups, Korean government (MSIT).
Abstract (Originalsprache)
Peptide and protein (PP) therapeutics are highly specific and potent biomolecules that treat chronic and complex diseases. However, their oral delivery is significantly hindered by enzymatic degradation, instability, and poor permeability through the gastrointestinal (GI) epithelium, resulting in low bioavailability. Various strategies have emerged as transformative solutions to address existing challenges, offering enhanced protection, stabilization, and absorption of PPs. These strategies primarily focus on two major challenges: protecting the PP against harsh conditions and enhancing permeation across the intestinal membrane. Innovative approaches such as pH modulation and incorporation of enzyme inhibitors are usually used to mitigate proteolytic degradation of PP during transit across the GI tract. In a similar vein, absorption enhancers and prodrug strategies facilitate epithelial transport, while targeted delivery systems focus on specific areas of the GI tract to enhance absorption. Likewise, mucus-penetrating and mucoadhesive strategies have enhanced retention and interaction with epithelial cells, effectively overcoming barriers like the mucus layer and tight epithelial junctions. Furthermore, structural modifications such as lipidation, peptide cyclization, and polyethylene glycosylation are promising alternatives to render stability, prolong circulation time, and membrane permeability. In particular, functional biomaterials, active targeting, and lymphatic transport strategies have provided new platforms for oral PP delivery. Advancing in materials science, nanotechnology, and the disruption of medical devices holds new frontiers to overcome barriers. Despite substantial advancements, the limited success in clinical translation underscores the urgency of innovative strategies. This review presents oral PPs as a promising platform, highlighting the key barriers and strategies to transform their therapeutic landscapes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Marine Bio-Food Science, Gangneung-Wonju National University, Gangneung 25457, Republic of Korea.
- NVience Inc., Seoul 04323, Republic of Korea.
ORCID-Profile: Kshitis Chandra Baral, Ki Young Choi
Förderung
- National Research Foundation of Korea
- Ministry of SMEs and Startups
- Korean government (MSIT)
- Ministry of Small and Medium-sized Enterprises (SMEs) and Startups (MSS), Korea
Zitieren
APA
Baral, K. C., & Choi, K. Y. (2025). Barriers and Strategies for Oral Peptide and Protein Therapeutics Delivery: Update on Clinical Advances. Pharmaceutics, 17(4), 397. https://doi.org/10.3390/pharmaceutics17040397
Vancouver
Baral KC, Choi KY. Barriers and Strategies for Oral Peptide and Protein Therapeutics Delivery: Update on Clinical Advances. Pharmaceutics. 2025;17(4):397. doi:10.3390/pharmaceutics17040397
BibTeX
@article{Baral2025,
author = {Baral, Kshitis Chandra and Choi, Ki Young},
title = {Barriers and Strategies for Oral Peptide and Protein Therapeutics Delivery: Update on Clinical Advances},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {4},
pages = {397},
doi = {10.3390/pharmaceutics17040397}
}
EUVIMED